NBIX · Neurocrine Biosciences Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $814.50M | - | $794.90M | $687.50M | $572.60M | - | $622.10M | $590.20M | $515.30M | - |
| Cost of Revenue | $13.80M | - | $14.00M | $11.30M | $9.20M | - | $8.00M | $9.20M | $7.50M | - |
| Gross Profit | $800.70M | - | $780.90M | $676.20M | $563.40M | - | $614.10M | $581.00M | $507.80M | - |
| R&D | $296.20M | - | $250.00M | $244.30M | $263.20M | - | $195.00M | $191.10M | $159.40M | - |
| SG&A | $318.50M | - | $291.60M | $286.30M | $276.50M | - | $234.30M | $242.00M | $243.10M | - |
| Total Operating Expenses | $621.10M | - | $555.90M | $541.90M | $549.00M | - | $438.30M | $444.80M | $416.00M | - |
| D&A | $7.20M | - | - | - | $6.60M | - | - | - | $5.30M | - |
| Operating Income | $193.40M | - | $239.00M | $145.60M | $23.60M | - | $183.80M | $145.40M | $99.30M | - |
| Interest Expense | - | - | - | - | - | - | - | - | $1.10M | - |
| Income Tax | $48.90M | - | $82.30M | $52.00M | $6.80M | - | $60.50M | $33.60M | ($8.90M) | - |
| Net Income | $197.90M | - | $209.50M | $107.50M | $7.90M | - | $129.80M | $65.00M | $43.40M | - |
| EPS - Basic | $1.97 | - | $2.11 | $1.09 | $0.08 | - | $1.28 | $0.64 | $0.43 | - |
| EPS - Diluted | $1.91 | - | $2.04 | $1.06 | $0.08 | - | $1.24 | $0.63 | $0.42 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $266.50M | $713.00M | $340.20M | $264.00M | $194.10M | $233.00M | $349.10M | $139.70M | $396.30M | $251.10M |
| Accounts Receivable | $768.10M | $686.80M | $728.00M | $595.70M | $516.00M | $479.10M | $481.10M | $468.20M | $450.70M | $439.30M |
| Inventory | $64.50M | $69.00M | $69.30M | $56.90M | $59.10M | $57.40M | $45.80M | $42.50M | $37.20M | $38.30M |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | $1.61B |
| Total Assets | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | $3.25B |
| Current Liabilities | $831.70M | $743.40M | $638.00M | $546.30M | $522.90M | $507.70M | $429.70M | $398.50M | $712.90M | $654.80M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816.10M | $795.80M | $1.09B | $1.02B |
| Stockholders' Equity | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B |
| Retained Earnings | $589.60M | $447.70M | $294.00M | $84.50M | ($5.30M) | $29.20M | $81.10M | ($48.70M) | ($113.70M) | ($157.10M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $145.80M | - | - | - | $64.80M | - | - | - | $130.30M | - |
| Investing Cash Flow | ($506.20M) | - | - | - | $14.20M | - | - | - | ($55.00M) | - |
| Financing Cash Flow | ($86.10M) | - | - | - | ($117.90M) | - | - | - | $69.90M | - |
| CapEx | $9.10M | - | - | - | $10.70M | - | - | - | $11.20M | - |
| Free Cash Flow | $136.70M | - | - | - | $54.10M | - | - | - | $119.10M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 98.3% | - | 98.2% | 98.4% | 98.4% | - | 98.7% | 98.4% | 98.5% | - |
| Operating margin | 23.7% | - | 30.1% | 21.2% | 4.1% | - | 29.5% | 24.6% | 19.3% | - |
| EBITDA margin | 24.6% | - | - | - | 5.3% | - | - | - | 20.3% | - |
| Net margin | 24.3% | - | 26.4% | 15.6% | 1.4% | - | 20.9% | 11.0% | 8.4% | - |
| Free cash flow margin | 16.8% | - | - | - | 9.4% | - | - | - | 23.1% | - |
| FCF / Net income | 0.69 | - | - | - | 6.85 | - | - | - | 2.74 | - |
| R&D / Revenue | 36.4% | - | 31.5% | 35.5% | 46.0% | - | 31.3% | 32.4% | 30.9% | - |
| SG&A / Revenue | 39.1% | - | 36.7% | 41.6% | 48.3% | - | 37.7% | 41.0% | 47.2% | - |
| Effective tax rate | 19.8% | - | 28.2% | 32.6% | 46.3% | - | 31.8% | 34.1% | -25.8% | - |
| Return on assets | 4.0% | - | 4.9% | 2.8% | 0.2% | - | 3.7% | 2.0% | 1.2% | - |
| Return on equity | 5.8% | - | 7.0% | 4.0% | 0.3% | - | 4.8% | 2.6% | 1.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.93 | 3.39 | 3.38 | 3.20 | 3.13 | 3.40 | 4.37 | 4.19 | 2.52 | 2.45 |
| Quick ratio | 2.85 | 3.30 | 3.27 | 3.10 | 3.02 | 3.28 | 4.26 | 4.08 | 2.47 | 2.40 |
| Cash ratio | 0.32 | 0.96 | 0.53 | 0.48 | 0.37 | 0.46 | 0.81 | 0.35 | 0.56 | 0.38 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | 90.3x | - |
| Equity multiplier | 1.44 | 1.42 | 1.42 | 1.44 | 1.45 | 1.44 | 1.30 | 1.32 | 1.46 | 1.46 |
| Liabilities / Assets | 0.31 | 0.30 | 0.30 | 0.31 | 0.31 | 0.30 | 0.23 | 0.24 | 0.31 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.19 | 0.18 | 0.16 | - | 0.18 | 0.18 | 0.15 | - |
| Inventory turnover | 0.21 | - | 0.20 | 0.20 | 0.16 | - | 0.17 | 0.22 | 0.20 | - |
| Days sales outstanding | 344d | - | 334d | 316d | 329d | - | 282d | 290d | 319d | - |
| Days inventory outstanding | 1706d | - | 1807d | 1838d | 2345d | - | 2090d | 1686d | 1810d | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 69.0x | - | 68.8x | 118.6x | 1382.5x | - | 92.9x | 218.5x | 328.4x | - |
| P / B | 4.0x | - | 4.8x | 4.7x | 4.5x | - | 4.4x | 5.7x | 6.0x | - |
| P / S | 16.7x | - | 18.1x | 18.5x | 19.8x | - | 19.3x | 24.2x | 27.7x | - |
| EV / EBITDA | 66.6x | - | - | - | 369.0x | - | - | - | 132.8x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 42.2% | - | 27.8% | 16.5% | 11.1% | - | 24.7% | 30.4% | 22.6% | - |
| Revenue CAGR (3y) | 24.7% | - | 27.0% | 22.0% | 22.6% | - | 28.1% | 26.9% | 29.6% | - |
| Revenue CAGR (5y) | 28.0% | - | 25.2% | 17.9% | 19.3% | - | 22.9% | 26.3% | 30.1% | - |
| Gross profit growth (YoY) | 42.1% | - | 27.2% | 16.4% | 10.9% | - | 25.9% | 31.7% | 23.3% | - |
| Operating income growth (YoY) | 719.5% | - | 30.0% | 0.1% | -76.2% | - | 30.2% | 97.6% | - | - |
| Net income growth (YoY) | 2405.1% | - | 61.4% | 65.4% | -81.8% | - | 56.2% | -31.9% | - | - |
| EPS growth (YoY) | 2287.5% | - | 64.5% | 68.3% | -81.0% | - | 51.2% | -33.7% | - | - |
| EPS CAGR (3y) | - | - | 43.5% | - | -17.0% | - | 75.3% | 13.6% | 8.4% | - |
| EPS CAGR (5y) | 42.1% | - | - | 5.5% | -27.2% | - | 17.2% | 3.1% | - | - |
| FCF growth (YoY) | 152.7% | - | - | - | -54.6% | - | - | - | - | - |
| FCF CAGR (5y) | 10.5% | - | - | - | 8.0% | - | - | - | - | - |
| Book value growth (YoY) | 34.4% | 25.6% | 10.5% | 7.4% | 6.3% | 16.0% | 35.8% | 35.4% | 41.7% | 30.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.51B totalReportable Segment$2.51B · 100.0%
Product / service
$2.86B totalProduct$2.83B · 99.1%
Collaboration Revenue$26.60M · 0.9%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing NEUROCRINE BIOSCIENCES INC against the 5 most active filers in the same SIC group.